Collaboration on innovative drug synthesis routes
Pantarhei Bioscience has signed a research agreement with The Van’t Hoff Institute for Molecular Science’s Biocatalysis group (HIMS). The Biocatalysis group at HIMS focuses on the application of novel enzymes for the synthesis of fine chemicals and pharmaceuticals. Aim of this collaboration with Associate Prof. Anett Schallmey, who was recently appointed at HIMS, is to develop a novel biocatalytic route towards the synthesis of a promising drug candidate for application in women’s health and oncology.
ESHRE, June 29-July 2, 2014, Munich, Germany
On 30 June 2014 Yvette Zimmerman presented a poster at the ESHRE meeting in Munich, Germany on the novel oral contraceptive concept Androgen Restored Contraception (ARC). ARC is aiming at maintaining physiological androgen levels in women using a combined oral contraceptive (COC) by the addition of the natural human adrenal hormone dehydroepiandrosterone (DHEA). The endocrine and clinical effects of ARC were evaluated in a series of double-blind placebo-controlled clinical studies. The serious loss of androgens during COC-use, especially of free testosterone, was confirmed and significant clinical effects of normalising testosterone on sexual functioning and mood were found. Detailed results were presented in a poster entitled: “Two randomised clinical studies investigating the endocrine and clinical effects of normalising testosterone levels during oral contraception.” The further phase 3 development of the ARC concept will be discussed with the Swedish regulatory agency on September 4 in Uppsala.